Skip to main
SOPH

SOPH Stock Forecast & Price Target

SOPH Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sophia Genetics is a rapidly growing healthcare technology company with a strong presence in the United States and a global customer base. They have a proven track record of revenue growth and customer acquisition, supported by their innovative use of artificial intelligence in medical data analysis. The company's strategic partnerships and investments in their data management system demonstrate their commitment to continuous improvement and expansion. While facing challenges in their biopharma division, SOPH is expected to reach profitability in the medium term, making them an attractive stock investment opportunity.

Bears say

Sophia Genetics is expanding its revenue through its relationship with the Mayo Clinic and signing 60 customers for its MSK ACCESS application, but has not yet generated significant revenue from these customers. Additionally, only a small percentage of customers are utilizing multiple applications, raising concerns about SOPH's land and expand model. Furthermore, while the new exome product is promising, it is unclear how quickly SOPH will see revenue generation from this product given the slow adoption of their other offerings.

SOPH has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sophia Genetics SA (SOPH) Forecast

Analysts have given SOPH a Strong Buy based on their latest research and market trends.

According to 2 analysts, SOPH has a Strong Buy consensus rating as of May 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sophia Genetics SA (SOPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.